Kaplan-Meier curves showing effect of NPM1 VAF. (A) Effect of high NPM1 VAF on OS in the entire cohort (12.1 months vs not reached; P < .0001). (B) Effect of high NPM1 VAF on EFS in the entire cohort (7.5 vs 65.44 months; P < .0001). (C) Effect of high NPM1 VAF on EFS in patients censored at the time of any SCT in CR1 (6.7 vs 31.0 months; P = .006). (D) Effect of high NPM1 VAF (n = 7) on EFS in patients treated with SCT in CR1 (n = 45; 11.0 months vs not reached; P = .0004).